Carregando…
QURE
uniQure N.V.
NASDAQ· Healthcare· Biotechnology
$48.72-1.69%
Indicadores
- Market cap
- $3.38B
- P/L
- —
- P/L projetado
- —
- P/VP
- 10.4x
- Dividend yield
- —
- EPS
- -$3.99
- ROE
- -157.61%
- Margem líquida
- 0.00%
- Crescimento de receita
- +11.00%
- Beta
- 0.94
- Máxima 52 semanas
- $71.50
- Mínima 52 semanas
- $8.73
Histórico
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos demonstrativos anuais; os dividendos, dos próprios pagamentos, que alcançam mais anos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Investidores posicionados
Grandes gestores que reportaram esta ação no 13F mais recente.
Sobre a empresa
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- 221
- Amsterdam, Netherlands
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.